Intuitive Surgical's Earnings Top Estimates as It Boosts Sales of Surgical Robots

Intuitive Surgical (ISRG) reported fourth-quarter earnings that topped analysts’ expectations as it boosted sales of its surgical robots. The medical device maker reported fourth-quarter revenue of $2.41 billion, a 25% jump year-over-year and above the analyst consensus compiled by Visible Alpha. Earnings came in at $686 million, or $1.88 per share, up from $606 million, or $1.69 per share, a year ago and also beat expectations.

Intuitive Surgical said the number of procedures performed with its da Vinci minimally invasive surgical devices increased 18% from a year earlier. The company said it installed 493 da Vinci systems in the period, compared to 415 a year ago. The company said it expects da Vinci procedures this year to grow 13% to 16% from 2024. Its adjusted gross profit margin is expected to fall between 1 to 2 percentage points, but that doesn’t account for potential new tariffs, which could have a “material” impact, the company said.

Intuitive Surgical shares wavered between slight gains and losses in extended trading Thursday following the release. The stock closed at an all-time high a day earlier and has gained about 62% over the past year through Thursday's close.



The Sunnyvale, Calif., medical-technology company reported a profit of $685.7 million, or $1.88 a share, compared with $606.2 million, or $1.69 a share, for the same quarter last year. Adjusted per-share earnings were $2.21, beating the $1.79 that analysts were expecting, according to FactSet. Revenue increased 25%, to $2.41 billion. Analysts surveyed by FactSet had forecast sales of $2.25 billion.

The company said procedures with its da Vinci surgical system were up 18% from the year-ago quarter, while its installed base was up 15%. Its da Vinci surgical system is a robotic system used to perform several minimally-invasive surgeries including prostatectomies, cardiac valve repairs and gynecologic surgeries.

For 2025, Intuitive Surgical expects worldwide da Vinci procedures to increase between 13% and 16%, slightly lower than the 17% rise it posted in 2024.



Intuitive Surgical's strong performance and forward outlook are outstanding, and investors have noticed. Shares of the well-established medical technology business rose 62% during the 12-month period that ended Jan. 22, 2025. While the company's stock has risen significantly, it's still a good time to buy Intuitive Surgical, as its robotic surgery systems continue to gain market share and its earnings and revenue growth remain strong. However, investors should be aware of the risks involved with buying a stock at such a high valuation and monitor the company's performance and any potential changes in guidance or market conditions that could impact the stock price.